Omics Technologies Market Revenue and Forecast by 2035
Published: 12 Dec 2025
Author: Precedence Research
Omics Technologies Market Revenue and Trends 2026 to 2035
The global omics technologies market is expanding due to increasing applications in drug discovery, diagnostics, clinical research, and personalized treatment development. Rising demand for deeper molecular insights into diseases, combined with falling sequencing costs and breakthroughs in multi-omics and data-driven analytics, is fuelling unprecedented adoption across research, diagnostics, and drug development sectors.
What Are the Key Drivers That Are Influencing the Growth of the Omics Technologies Market?
The market for omics technologies is experiencing rapid growth due in large part to increasing requirements for personalized health care and translational medicine. Researchers and doctors are using genomic, transcriptomic, proteomic, and epigenetic information to gain additional insight into biology, and they are using these tools to determine how diseases progress through biological pathways, find biomarkers for disease, and formulate individualized treatment plans. With the dramatic decline in the cost and time required to complete a sequence run, even smaller laboratories and research centres are now able to incorporate omics into their daily operation.
In addition, the increasing number of pharmaceutical companies developing new drugs to combat complex diseases, the increasing amount of money invested in drug research and development, and the growing number of partnerships between the biotechnology industry and academic institutions have all contributed to an increase in demand for the latest omics technologies
Segment Insights
- By product type, sequencing platforms dominated the market in2024 due to their high throughput, flexibility, and ability to use one infrastructure to support multiple omics.
- By omics type, the genomics segment dominated the market, due to the foundational genetic insight provided by genomics, which is critical for many areas of research and for genomics-based diagnostic testing.
- By deployment type, the on-premises segment is the dominant segment because of the importance of data protection, compliance, and the need to control access to sensitive data generated in a research or diagnostic environment.
- By application, the drug discovery and development segment currently has the largest share of the market, as target validation, biomarker discovery, and mechanistic studies are becoming an essential part of modern therapeutic development pipelines.
By technology/mode of action, next-generation sequencing (NGS) is the dominant segment and most important technology because of its ability to increase throughput, to be very cost-effective, and to provide a fast and flexible method for studying multiple omics types. - By end user, academic/research institutes are currently dominating the market, generating large amounts of exploratory research data and embracing multi-omics as part of their basic science research and translational studies, and in developing new therapies.
- By sample type, the tissue sample segment is attributed to its high-quality genetic/molecular data content that provides the most relevant information for studies of disease and/or use of pathology/biomarkers in research.
Regional Insights
North America has been and continues to be the leading region worldwide due to its extensive research capabilities, substantial funding for research and development, and high adoption of genomics and multi-omics technologies across hospitals, clinical laboratories, and pharmaceutical settings. The region benefits from advanced sequencing platforms that support whole-genome, whole-exome, transcriptomic, and epigenomic analyses at scale. National programs such as the All of Us Research Program in the United States, which aims to gather genomic and health data from more than one million participants, strengthen downstream demand for multi-omics data processing and analytics.
Robust regulatory frameworks, including guidance from the U.S. Food and Drug Administration on next-generation sequencing in clinical diagnostics, provide clarity for laboratories integrating multi-omics workflows into routine testing. The presence of global leaders in sequencing, cloud bioinformatics, and computational biology further reinforces North America’s dominant position as the central hub for genomics-driven precision medicine.
The Asia Pacific region is experiencing the most rapid growth, driven by substantial investments in biotechnology, large-scale national genomics programmes, and rising demand for precision medicine across emerging and advanced economies. Countries such as China, India, South Korea, Japan, and Singapore are expanding genomic sequencing capacity through initiatives like China’s Precision Medicine Initiative, India’s GenomeIndia Project, and Japan’s Tohoku Medical Megabank Organisation, all of which generate vast multi-omics datasets that require specialized infrastructure for processing and integration.
Healthcare systems across the region are adopting omics-based approaches to improve early disease detection, pharmacogenomics-guided treatment decisions, and population-scale health research. Collaborative research networks between universities, government laboratories, and private-sector biotech firms continue to accelerate innovation, while rapid growth in cloud adoption and AI-driven bioinformatics supports the expansion of advanced analytics capabilities. These combined factors establish Asia Pacific as the fastest-growing market for genomics and multi-omics solutions.
Omics Technologies Market Coverage
| Report Attribute | Key Statistics |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2025 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa |
Recent Developments
- On October 1, 2025, Illumina introduced a new business division called BioInsight to provide large-scale multiomic data assets, advanced analytics, and AI-powered bioinformatics tools aimed at accelerating drug target discovery, improving biological pathway understanding, and supporting large-scale multimodal research collaborations.(Source: https://www.illumina.com)
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7196
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344